See more : Deep Lake Capital Acquisition Corp. (DLCAW) Income Statement Analysis – Financial Results
Complete financial analysis of Willow Biosciences Inc. (CANSF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Willow Biosciences Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Silicom Ltd. (SILC) Income Statement Analysis – Financial Results
- Saudi American Holdings Corp. (SAHN) Income Statement Analysis – Financial Results
- RTX A/S (0NQJ.L) Income Statement Analysis – Financial Results
- Norinco International Cooperation Ltd. (000065.SZ) Income Statement Analysis – Financial Results
- Era Co., Ltd. (002641.SZ) Income Statement Analysis – Financial Results
Willow Biosciences Inc. (CANSF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.willowbio.com
About Willow Biosciences Inc.
Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical product industries in Canada. The company also produces cannabidiol, cannabigerol, and varin cannabinoids, such as cannabigerovarin, cannabidivarin, and tetrahydrocannabivarin. Willow Biosciences Inc. was incorporated in 1981 and is headquartered in Calgary, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.17M | 821.00K | 133.00K | 10.00K | 4.58K | 16.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.83M | 7.47M | 11.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 116.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -659.00K | -6.65M | -11.40M | 10.00K | 4.58K | 16.91K | 0.00 | 0.00 | 0.00 | -116.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -56.23% | -810.23% | -8,571.43% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.80M | 7.47M | 11.51M | 7.26M | 2.67M | 387.48K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.60M | 8.29M | 7.79M | 6.42M | 8.24M | 961.60K | 628.86K | 873.74K | 721.12K | 925.69K | 1.04M | 625.29K | 928.26K | 887.93K | 2.00M | 1.01M | 1.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 420.00K | 808.00K | 817.00K | 0.00 | 0.00 | 588.31K | 0.00 | 31.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 89.13K | 76.39K | 36.47K | 87.92K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.29K | 7.10K |
| SG&A | 6.02M | 9.10M | 8.60M | 6.42M | 8.24M | 1.55M | 628.86K | 873.74K | 721.12K | 925.69K | 1.04M | 625.29K | 928.26K | 977.07K | 2.08M | 1.04M | 2.07M | 420.83K | 442.64K | 193.66K | 83.25K | 70.10K | 165.87K | 179.97K | 2.29K | 7.10K |
| Other Expenses | 1.54M | 0.00 | -22.00K | 0.00 | 0.00 | 0.00 | 6.61K | 30.89K | 20.08K | 60.32K | 75.13K | 50.00K | 0.00 | 3.51K | 93.90K | -84.32K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.35M | 19.22M | 23.31M | 16.86M | 13.08M | 1.66M | 628.86K | 873.74K | 721.12K | 925.80K | 1.04M | 626.08K | 929.43K | 979.54K | 2.08M | 1.05M | 2.07M | 420.83K | 442.64K | 193.66K | 83.25K | 70.10K | 165.87K | 179.97K | 114.44K | 202.12K |
| Cost & Expenses | 14.35M | 19.22M | 23.31M | 16.86M | 13.08M | 1.66M | 628.86K | 873.74K | 721.12K | 925.80K | 1.04M | 626.08K | 929.43K | 979.54K | 2.08M | 1.05M | 2.07M | 420.83K | 442.64K | 193.66K | 83.25K | 70.10K | 165.87K | 179.97K | 114.44K | 202.12K |
| Interest Income | 267.00K | 300.00K | 414.00K | 155.00K | 112.90K | 0.00 | 0.00 | 0.00 | 2.00 | 115.00 | 238.00 | 43.00 | 1.89K | 7.35K | 1.77K | 17.60K | 14.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.56K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 142.00K | 26.00K | 27.00K | 40.00K | 48.14K | 0.00 | 21.96K | 2.26K | 0.00 | 0.00 | 1.78K | 11.41K | 28.14K | 1.28K | 1.68K | 1.48K | 1.30K | 234.00 | 248.00 | 24.13K | 126.51K | 0.00 | 0.00 | 3.19K | 0.00 | 0.00 |
| Depreciation & Amortization | 1.83M | 2.65M | 3.19M | 3.18M | 2.17M | 46.39K | 38.38K | 30.18K | 609.49K | 116.00 | 382.00 | 787.00 | 1.17K | 2.48K | 3.73K | 3.87K | 1.03K | 0.00 | 0.00 | 0.00 | 192.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -11.63M | -15.45M | -2.92M | -30.72M | -43.93M | -1.60M | -1.52M | -1.07M | -4.37M | -865.26K | -962.89K | -625.25K | -951.54K | -969.72K | -1.98M | -1.11M | -2.07M | -420.83K | -442.64K | -193.66K | 13.12K | -70.10K | -165.87K | -179.97K | -114.44K | -202.12K |
| EBITDA Ratio | -992.06% | -1,882.34% | -14,712.78% | -135,090.00% | -235,507.88% | -9,449.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -13.18M | -18.39M | -23.33M | -23.06M | -46.15M | -1.64M | -622.25K | -873.74K | -721.12K | -925.80K | -1.04M | -626.08K | -954.60K | -980.82K | -2.08M | -1.05M | -2.07M | -420.83K | -442.64K | -193.66K | -179.62K | -70.10K | -165.87K | -179.97K | -114.44K | -202.12K |
| Operating Income Ratio | -1,124.74% | -2,240.32% | -17,541.35% | -230,610.00% | -1,006,696.42% | -9,723.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 148.00K | 3.63M | 17.19M | -10.89M | 561.00K | 0.00 | -931.67K | -1.46M | -85.05K | 60.43K | -348.54K | -1.17M | -462.51K | -2.35M | -1.13M | -313.85K | 25.48K | -234.00 | -248.00 | 0.00 | -96.37K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -13.03M | -14.76M | -6.14M | -33.95M | -46.15M | -1.64M | -1.86M | -2.33M | -1.31M | -865.37K | -1.39M | -1.80M | -1.42M | -3.33M | -3.21M | -1.36M | -2.05M | -421.06K | -442.89K | 0.00 | -275.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -1,112.12% | -1,797.93% | -4,616.54% | -339,460.00% | -1,006,696.42% | -9,723.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -5.00K | 53.00K | 27.00K | 40.00K | -1.58M | -114.75K | -9.81K | 2.26K | -2.00 | 60.32K | 76.90K | 11.41K | 28.14K | -118.00K | -157.00K | -211.04K | -394.90K | -16.65K | -52.54K | 217.79K | 30.14K | 70.21K | 163.31K | 183.16K | 114.44K | 202.12K |
| Net Income | -13.03M | -14.81M | -6.14M | -33.95M | -44.57M | -1.64M | -1.86M | -2.33M | -1.31M | -865.37K | -1.39M | -1.80M | -1.42M | -3.22M | -3.06M | -1.15M | -1.65M | -404.41K | -390.35K | -217.79K | -306.13K | -70.21K | -163.31K | -183.16K | -114.44K | -202.12K |
| Net Income Ratio | -1,111.69% | -1,804.38% | -4,616.54% | -339,460.00% | -972,220.55% | -9,723.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.10 | -0.12 | -0.05 | -0.41 | -0.62 | -0.75 | -2.58 | -8.37 | -9.72 | -10.53 | -31.15 | -128.95 | -106.73 | -267.54 | -310.63 | -177.90 | -347.50 | -118.01 | -158.36 | -126.04 | -300.12 | -59.80 | -139.10 | -156.01 | -97.47 | -17.50 |
| EPS Diluted | -0.10 | -0.12 | -0.05 | -0.41 | -0.62 | -0.75 | -2.58 | -8.37 | -9.72 | -10.53 | -31.15 | -128.95 | -106.73 | -267.54 | -310.63 | -177.90 | -347.50 | -118.01 | -158.36 | -126.04 | -300.12 | -59.80 | -139.10 | -156.01 | -96.98 | -17.50 |
| Weighted Avg Shares Out | 124.24M | 123.66M | 119.99M | 81.99M | 72.07M | 2.19M | 721.07K | 278.32K | 134.77K | 82.21K | 44.53K | 13.96K | 13.28K | 12.02K | 9.84K | 6.48K | 4.76K | 3.43K | 2.47K | 1.73K | 1.02K | 1.17K | 1.17K | 1.17K | 1.17K | 11.55K |
| Weighted Avg Shares Out (Dil) | 124.24M | 123.66M | 119.99M | 81.99M | 72.07M | 2.19M | 721.07K | 278.32K | 134.77K | 82.21K | 44.53K | 13.96K | 13.28K | 12.02K | 9.84K | 6.48K | 4.76K | 3.43K | 2.47K | 1.73K | 1.02K | 1.17K | 1.17K | 1.17K | 1.18K | 11.55K |
Willow Biosciences primes investors for strong 2024 after transformative 2023
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) said it expects to more than double revenue in 2024 as it closes new partnership development agreements. Updating investors on its achievements in 2023 and its plans for the year ahead, the company said it...
WILLOW PLANS FOR SIGNIFICANT GROWTH IN 2024 ON THE BACK OF A SUCCESSFUL 2023
Estimated FY 2023 revenues in excess of $1.3 million is a record year for the Company Anticipate closing at least three new partnership development agreements including one for our corticosteroid API program, and one new commercial agreement under an existing...
Willow Biosciences set to generate revenue from partnership with biopharma firm as early as 2024
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) expects to generate commercial revenue from an expanded partnership with a Nasdaq-listed biopharmaceutical company as early as 2024, the company's CEO Chris Savile has highlighted. Savile sat down with Proactive to discuss the company's recent...
Willow Biosciences advances development program with leading innovative biopharma company
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) said it is advancing a program with a Nasdaq-listed biopharmaceutical company to develop precise, concise manufacturing routes to advanced intermediates and high-value active pharmaceutical ingredients. After the Phase 1 feasibility program that applied Willow's BioOxi...
WILLOW AND LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY ADVANCE DEVELOPMENT PROGRAM TO MANUFACTURE SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
Program brings immediate R&D revenue and first commercial supply revenue as early as 2024 Program further validates Willow's BioOxi™ technology and focus on commercial execution and aligns with its strategic focus on near term revenue generation SUNNYVALE, Calif., Dec. 7, 2023...
Willow Biosciences reduces cash burn, achieves record revenue in 3Q
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) reported record quarterly revenue of C$674 million for the third quarter, up from C$49 million in the year-ago quarter, and revenue for the first nine months of 2023 of C$1.08 million. The biotechnology company said that...
WILLOW BIOSCIENCES ANNOUNCES COMPLETION OF PREVIOUSLY ANNOUNCED CONVERTIBLE DEBENTURE FINANCING
CALGARY, AB , Oct. 10, 2023 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, is pleased to announce the completion of its previously announced offering...
Willow Biosciences and Suanfarma partner to develop large volume anti-infective API through precision fermentation
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) told investors it has partnered with Spanish life science company Suanfarma to bring sustainably sourced products to market using their joint capabilities. The companies have entered a collaboration agreement for a cell line productivity optimization...
WILLOW AND SUANFARMA ANNOUNCE COLLABORATION ON DEVELOPMENT OF LARGE VOLUME ANTI-INFECTIVE API THROUGH PRECISION FERMENTATION
SUNNYVALE, Calif. , Oct. 3, 2023 /PRNewswire/ - Willow Biosciences Inc., ("Willow") (TSX: WLLW) (OTCQB: CANSF) and SUANFARMA today jointly announced execution of a collaboration agreement for a cell line productivity optimization development program for manufacturing a large volume anti-infective...
Willow Biosciences announces $1.2M debt offering
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) announced a non-brokered private placement offering of convertible debenture units, with the goal of raising up to C$1.2 million. The Calgary-based firm plans to allocate proceeds to support the commercialization and development of its pipeline...
Source: https://incomestatements.info
Category: Stock Reports